YS Biopharma Co., Ltd. reported positive interim results from a pivotal Phase 3 clinical study of its PIKA Rabies Vaccine on April 9, 2024. The event is significant for equity investors as it indicates progress in their vaccine development.
AI Assistant
LAKESHORE BIOPHARMA CO LTD
2024
6 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.